FATE - Fate Therapeutics: The iPSC Innovator With A Candidate-Laden Pipeline

• Fate Therapeutics, an immuno-oncology biopharmaceutical company, has novel core technology with the potential to become a strong competitor in the sector.
• The company's iPSC-based NK-cell and T-cell immunotherapies are at the forefront of innovation in one of science's most cutting-edge and well-funded fields.
• All drug candidates in the pipeline are, however, early stage; investors can only project preliminary positive results with no prior successes as a foundation to build on.
• Having risen over 120% in Q4 2020, Fate Therapeutics is overextended from a value standpoint; that said, there is a strong case for a growth-based thesis in its technology.

For further details see: